Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Experts suggest Fukushima clean-up workers store blood cells for future use

Experts suggest Fukushima clean-up workers store blood cells for future use

Novel drug holds potential against resistant chronic myeloid leukemia

Novel drug holds potential against resistant chronic myeloid leukemia

Protest over planned cuts to Australian medical research funding

Protest over planned cuts to Australian medical research funding

CINJ experts to comment on vaccine therapy and biomedical informatics

CINJ experts to comment on vaccine therapy and biomedical informatics

NCI, ASH, AMEH join to improve care for patients with AML

NCI, ASH, AMEH join to improve care for patients with AML

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

IBM discovers biodegradable nanoparticles that seek out and destroy drug-resistant bacteria

IBM discovers biodegradable nanoparticles that seek out and destroy drug-resistant bacteria

Study reveals few genes involved with lymphoma shared by dogs and humans

Study reveals few genes involved with lymphoma shared by dogs and humans

Study: New cancer drug shrinks tumors in mouse model with few side effects

Study: New cancer drug shrinks tumors in mouse model with few side effects

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen launches InformThyroid, a panel of molecular markers

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

Scientists develop new method to identify factors that suppress cancer gene expression

Scientists develop new method to identify factors that suppress cancer gene expression

Zebrafish research suggests new drug targets and markers to help treat melanoma

Zebrafish research suggests new drug targets and markers to help treat melanoma

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

Court grants motion to dismiss Cryo-Cell International lawsuit against Cord Blood America

Court grants motion to dismiss Cryo-Cell International lawsuit against Cord Blood America

Artemisinin or high-pressure oxygen can boost natural cancer remedy

Artemisinin or high-pressure oxygen can boost natural cancer remedy

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

Aflac announces $1.06 million scholarship awards for cancer research

Aflac announces $1.06 million scholarship awards for cancer research

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.